Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30887571 | 1.00 | ABCB1 (0.51) | ABCB1LTA4HMAPK14NPC1RAB9A | |
| SCHEMBL2339072 | 0.87 | LTA4H (0.64) | ABCB1LTA4HMAPK14NPC1RAB9A | |
| SCHEMBL7237455 | 0.80 | NPC1 (0.68) | ABCB1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6206351 | 0.79 | LTA4H (0.58) | LTA4HMAPK14NPC1RAB9AMAPT | |
| SCHEMBL6026657 | 0.76 | NPC1 (0.74) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL11755567 | 0.75 | CHRNB2 (0.46) | LTA4HMAPK14NPC1RAB9AMAPT | |
| SCHEMBL25389540 | 0.74 | NPC1 (0.49) | ABCB1LTA4HMAPK14NPC1RAB9A | |
| SCHEMBL8883647 | 0.73 | ABCB1 (0.50) | ABCB1LTA4HMAPK14MAPTSMN1; SMN2 | |
| SCHEMBL29407668 | 0.73 | GRM5 (0.49) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL2547749 | 0.73 | GRM5 (0.49) | HTTMEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4377298-A1 | PROTEIN SECRETION INHIBITORS | Gate Bioscience, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117999256-A | Protein secretion inhibitor | 分子门生物科技公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | ABCB1 2049/4885LTA4H 2216/4885MAPK14 359/4885 |
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ABCB1 1253/4885LTA4H 3131/4885MAPK14 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.